Register Here

2018 Executive Sponsors

Adaptive Biotechnologies
Imaging Endpoints
Isoplexis
Mitra Biotech
nanoString Technologies
NeoGenomics

2018 Associate Sponsors

Apogenix
BeiGene
Bioclinica
Boston Immunetech
Cancer Genetics
Celyad
Cofactor Genomics
Cytel
Defined health
Exicure
ICON
IQVIA
KIYATEC Inc
PAREXEL
Personalis
Oncorus
Replimune
Smart Analyst

2018 Supporting Sponsors

HTG Molecular

2018 Exhibitors

Axio Research
Caprion
Intrinsic Imaging
Provecs Medical

Supporting & Educational Partners

Trout Group
CIMT
Cancer Research Institute
Patient Empowerment
SITC

2018 Media Partners

BioCentury
BioPharm Insight
BioPharma Dive
CanBiotech
Endpoints News
Life Science Leader
Pharmalicensing
Pharmaphorum
PharmaVOICE
STAT
Technology Networks

The Premier Meeting Across all Stakeholders in Immuno-Oncology

 

Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO including:

  • Discovery / Preclinical Science

  • Translational Science

  • Clinical Development

  • Business Aspects

  • Investor Relations

  • Emerging Technologies

  • Biomarkers / Diagnostics

  • Trends in the Field

2018 IO360 main speakers

Overview


Dr Axel Hoos, GSK and Dr James Gulley, NCI, together led the design of the 4th annual Immuno-Oncology 360° program to include 70 speakers and over 60 talks. We are delighted to announce that Dr Andrew Baum  is confirmed as the investor relations plenary keynote.

Featured Speakers

 

Immuno-Oncology 360° provides the most up-to-date research, data and progress to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
  • Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof​
  • Receive the latest pre-clinical, translational and clinical data from academic and industry
  • Identify and gain a greater understanding of what assets are available for potential combinations  
  • Create and prioritize strategies targeted toward specific tumor types​
  • Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
  • Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next
  • Hear reports on industry trends from Endpoint News and BioCentury Innovations and a progress update on the Cancer Moonshot
  • Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
  • Obtain coverage on a wide range of emerging technologies

Please contact us at service@tcfllc.org if you have any questions. Thank you and we look forward to seeing you in February.

Sincerely,​

kate-bw-3

Kate Woda
Conference Director

Valerie Bowling New

Valerie Bowling
Executive Director

Meredith Sands
Executive Director, Business Development

onaleesmith-bw

Onalee Smith
Marketing Manager

elizabeth-bard-bw-2

Elizabeth Bard
Business Development Manager

geeta-new-bw

Geeta Bachani
Business Development Manager

Bridget Halstead
Senior Conference Planner

Tara Fennelly
Marketing Associate


Dr Daniel Chen, Genentech delivered a talk on cancer immunity cycle at IO360° 2017

Dr Patricia Keegan, FDA discussed Modified RECIST 1.1 at IO360° 2017

Trends & Collaborations Panel at IO360° 2017: From Left to Right: Dr Ramy Ibrahim, Parker Research Institute for Cancer Immunotherapy, Dr David Wholley, Foundation for the National Institutes of Health, Dr Jill O’Donnell-Tormey, Cancer Research Institute, Dr Daniel Chen, Genentech